In particular, the inactivation of CD24-Siglec-E pathway may worsen the condition, whereas CD24Fc therapy may alleviate metabolic disturbances caused by diet, including obesity, dyslipidemia, insulin resistance, and nonalcoholic steatohepatitis (NASH).Mechanistically, Siglec-E’s sialic acid-dependent recognition of CD24 induces the recruitment of SHP-1, which in turn suppresses metabolic inflammation and prevents metabolic syndrome (25). The gene discussed is CD24; the disease is Obesity.